| Bioactivity | DLinDMA, a ionizable cationic lipid, is a key lipid component of stable nucleic acid lipid particles (SNALPs) as a benchmark. DLinDMA is used for siRNA delivery[1]. | ||||||||||||
| Invitro | The structure of DLinDMA can be divided into three main regions: the hydrocarbon chains, the linker and the headgroup[1]. | ||||||||||||
| In Vivo | DLinDMA has virtually indistinguishable blood pharmacokinetic profiles in mice[1]. | ||||||||||||
| Name | DLinDMA | ||||||||||||
| CAS | 871258-12-7 | ||||||||||||
| Formula | C41H77NO2 | ||||||||||||
| Molar Mass | 616.06 | ||||||||||||
| Appearance | Liquid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Semple SC, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol. 2010 Feb;28(2):172-6. |
DLinDMA
CAS: 871258-12-7 F: C41H77NO2 W: 616.06
DLinDMA, a ionizable cationic lipid, is a key lipid component of stable nucleic acid lipid particles (SNALPs) as a bench
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.